EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mediator kinase inhibition reverses castration resistance of advanced prostate cancer

Jing Li, Thomas A Hilimire, Yueying Liu, Lili Wang, Jiaxin Liang, Balazs Gyorffy, Vitali Sikirzhytski, Hao Ji, Li Zhang, Chen Cheng, Xiaokai Ding, Kendall R Kerr und 14 weitere

Journal of Clinical Investigation · 15.05.2024 · 134 (10)

DOI: 10.1172/jci176709 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 28.03.2024. Verfasst von Jing Li und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Drug Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, Columbia, South Carolina, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Cyclin-Dependent Kinases, Cyclin-Dependent Kinase 8, Xenograft Model Antitumor Assays. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, BLRD VA, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mediator kinases CDK19 and CDK8, pleiotropic regulators of transcriptional reprogramming, are differentially regulated by androgen signaling, but both kinases are upregulated in castration-resistant prostate cancer (CRPC). Genetic or pharmacological inhibition of CDK8 and CDK19 reverses the castration-resistant phenotype and restores the sensitivity of CRPC xenografts to androgen deprivation in vivo. Prolonged CDK8/19 inhibitor treatment combined with castration not only suppressed the growth of CRPC xenografts but also induced tumor regression and cures. Transcriptomic analysis revealed that Mediator kinase inhibition amplified and modulated the effects of castration on gene expression, disrupting CRPC adaptation to androgen deprivation. Mediator kinase inactivation in tumor cells also affected stromal gene expression, indicating that Mediator kinase activity in CRPC molded the tumor microenvironment. The combination of castration and Mediator kinase inhibition downregulated the MYC pathway, and Mediator kinase inhibition suppressed a MYC-driven CRPC tumor model even without castration. CDK8/19 inhibitors showed efficacy in patient-derived xenograft models of CRPC, and a gene signature of Mediator kinase activity correlated with tumor progression and overall survival in clinical samples of metastatic CRPC. These results indicate that Mediator kinases mediated androgen-independent in vivo growth of CRPC, supporting the development of CDK8/19 inhibitors for the treatment of this presently incurable disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantCyclin-Dependent KinasesCyclin-Dependent Kinase 8Xenograft Model Antitumor AssaysProtein Kinase InhibitorsMaleHumansAnimalsMiceCell Line, TumorGene Expression Regulation, NeoplasticTumor Microenvironment

Stichwörter der Autor:innen

OncologyTherapeuticsTranscription

Substanzen

Cyclin-Dependent KinasesCyclin-Dependent Kinase 8Protein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Drug Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, Columbia, South Carolina, USA.
  • Senex Biotechnology Inc., Columbia, South Carolina, USA.
  • Division of Hematology-Oncology, Medical University of South Carolina, Charleston, South Carolina, USA.
  • Department of Bioinformatics, Semmelweis University, Budapest, Hungary.
  • Department of Biophysics, Medical School, University of Pecs, Pecs, Hungary.
  • Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences; Walter Reed National Military Medical Center; Henry M. Jackson Fo…

Förderung

  • NIGMS NIH HHS
  • BLRD VA
  • NCI NIH HHS
  • DOD
  • National Cancer Institute
  • National Institute of General Medical Sciences
  • U.S. Department of Defense

Zitieren

APA

Li, J., Hilimire, T. A., Liu, Y., Wang, L., Liang, J., Gyorffy, B., Sikirzhytski, V., Ji, H., Zhang, L., Cheng, C., Ding, X., Kerr, K. R., Dowling, C. E., Chumanevich, A. A., Mack, Z. T., Schools, G. P., Lim, C. U., Ellis, L., Zi, X., …, & Chen, M. (2024). Mediator kinase inhibition reverses castration resistance of advanced prostate cancer. Journal of Clinical Investigation, 134(10). https://doi.org/10.1172/jci176709

Vancouver

Li J, Hilimire TA, Liu Y, Wang L, Liang J, Gyorffy B, et al. Mediator kinase inhibition reverses castration resistance of advanced prostate cancer. Journal of Clinical Investigation. 2024;134(10). doi:10.1172/jci176709

BibTeX
@article{Li2024,
  author = {Li, Jing and Hilimire, Thomas A and Liu, Yueying and Wang, Lili and Liang, Jiaxin and Gyorffy, Balazs and Sikirzhytski, Vitali and Ji, Hao and Zhang, Li and Cheng, Chen and Ding, Xiaokai and Kerr, Kendall R and Dowling, Charles E and Chumanevich, Alexander A and Mack, Zachary T and Schools, Gary P and Lim, Chang-Uk and Ellis, Leigh and Zi, Xiaolin and Porter, Donald C and Broude, Eugenia V and McInnes, Campbell and Wilding, George and Lilly, Michael B and Roninson, Igor B and Chen, Mengqian},
  title = {Mediator kinase inhibition reverses castration resistance of advanced prostate cancer},
  journal = {Journal of Clinical Investigation},
  year = {2024},
  volume = {134},
  number = {10},
  doi = {10.1172/jci176709}
}
Kostenlos starten →